Interim data from three independent studies of Symbol Swap, a NeuLogiq® Platform two-minute tablet-based digital symbol-coding task will be presented as a measure for pre-enrichment of Alzheimer’s disease (AD) clinical trials.
Poster presentation scheduled for the Alzheimer’s Association International Conference (AAIC) 2026 on Wednesday, July 15 in London.
First Published: 8 July, 2026
Cumulus Neuroscience will present interim findings on Symbol Swap, a digital Digit Symbol Substitution Task at the Alzheimer’s Association International Conference 2026 in London, United Kingdom. The work was conducted in collaboration with the University of Bath and the University of Bristol.
The abstract was accepted by the AAIC Scientific Program Committee for poster presentation. Symbol Swap is a two-minute, tablet-based implementation of the classic Symbol Coding (Digit Symbol Substitution) Task that measures executive function. Across three independent studies, the task’s pre-enrichment performance was compared head-to-head with traditional cognitive screeners and with biomarker-defined Alzheimer’s pathology.
Cumulus poster presentation details are as follows:
Session Title: Developing Topics: Clinical Manifestations
Poster Title: A Brief Digital Symbol-Coding Task Outperforms Clinical Benchmarks For Alzheimer’s Trial Pre-enrichment
Poster Number: 1229
Date & Location: Wednesday, July 15, Exhibit Hall, Excel London
“Traditional cognitive screeners such as the MoCA and ADAS-Cog were never designed for early-stage Alzheimer’s trials, where cognitive change is subtle and easily masked by education, practice effects or compensatory strategies. That contributes to screen-failure rates that can exceed 40% in mild AD studies and rise above 75–85% in prodromal and preclinical cohorts,” said Dr. Brian Murphy, PhD, Cumulus Co-Founder and CSO. “With Symbol Swap, we set out to test whether a brief, patient-friendly digital task could do the heavy lifting of much longer assessments. The interim data we will present at AAIC are an encouraging step toward scalable, low-cost tools that help identify the right participants earlier — before costly PET or CSF screening. We are deeply grateful to all the study participants and collaborators who made this work possible.”
Scalable, low-cost tools are needed to identify individuals most likely to show early Alzheimer’s pathology or measurable cognitive decline before full clinical assessment and PET or CSF screening. NeuLogiq is a multimodal digital endpoint platform deployed in CNS clinical trials today, featuring patient-friendly digital versions of well-validated assessments that measure multiple domains of brain function. Full results will be shared during the poster session.
A second poster will be presented by Dr. James Rowe, Professor of Cognitive Neurology at the University of Cambridge and Chief Investigator on CNS-101, a first-of-its-kind study which was focused on measuring functional neurophysiology with the NeuLogiq Platform at home in patients living with mild Alzheimer’s dementia:
Session Title: Biomarkers
Poster Title: Multi-domain Digital Endpoints for Decentralized Alzheimer’s Trials: Experience from the CNS-101 Study (NeuLogiq®)
Poster Number: 2627
Date & Location: Tuesday, 14 July, Exhibit Hall, Excel London
About Alzheimer’s
Alzheimer’s is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, difficulty with language and communication, mood swings, and changes in behavior and personality. While there is no known cure, there are currently over one hundred Alzheimer’s disease clinical trials underway.
Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function. To learn more, visit www.cumulusneuro.com.
About Cumulus Neuroscience
With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing NeuLogiq®, an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world’s leading pharma companies, the platform enables decentralized trials and is already making a difference in the development of therapies for Alzheimer’s Disease, depression and schizophrenia.
Designed to provide an industry-wide standard for real-world measurement of disease progression, Cumulus combines patented technology, in-house expertise and key industry partnerships to capture large amounts of real-world, clinical data repeated over time, across multiple behavioral and physiological domains — in the clinic and in the patient’s home — all with an EEG headset synced to a novel, tablet-based neuro-assessment platform. Together with machine learning (ML) analytics and the world’s largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.
FOR MORE INFORMATION
Tina Sampath
Tina.Sampath@cumulusneuro.com